Evolus, Inc. Common Stock
6.86-0.18 (-2.56%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · EOLS · USD
Key Stats
Market Cap
443.74MP/E (TTM)
-Basic EPS (TTM)
-0.97Dividend Yield
0%Recent Filings
8-K
Evolus names new CFO
Evolus appointed Tatjana Mitchell as Chief Financial Officer effective September 8, 2025, bringing her 20+ years of finance leadership from Experian and Zulily to drive revenue growth and operational scaling. She'll earn a $490,000 base salary, $100,000 signing bonus, 55% target annual incentive, and $1.5 million in equity grants vesting over four years. Mitchell joins as Evolus pushes profitability in aesthetics. Her expertise bolsters strategic execution amid market expansion risks.
8-K
Evolus Q2 revenue up 4%
Evolus reported Q2 2025 net revenue of $69.4 million, up 4% from last year despite softening U.S. toxin demand, fueled by $9.7 million from the blockbuster Evolysse launch and robust international sales. CEO David Moatazedi steps in as interim Principal Financial Officer on August 1, while CMO Tomoko Yamagishi-Dressler exits August 22 with severance. Cost cuts promise $25 million in non-GAAP savings; guidance resets to $295–$305 million revenue, targeting Q4 profitability. Tariffs loom, but impact stays minimal.
10-Q
Q2 FY2025 results: Revenues $69.4M (+3.7% YoY), driven by Evolysse™ launch. Net loss $17.1M vs $11.4M YoY. Cash $61.7M. Debt $145.5M. Reaffirmed FY25 revenue $295-305M.
Evolus, Inc. reported Q2 FY2025 results with net revenues of $69.4 million, up 3.7% YoY, driven by $9.7 million from Evolysse™ launch, offsetting Jeuveau® decline. Gross margin was 65.3%, down from 70.3% due to product mix. Operating expenses rose 13% to $56.7 million from Evolysse™ commercialization. Net loss was $17.1 million, up from $11.4 million YoY, with EPS at ($0.27) vs ($0.18). Cash was $61.7 million, down from $87.0 million, after $40.4 million operating cash use. Full-year revenue guidance reaffirmed at $295-305 million. Balance sheet showed $145.5 million debt, $18.7 million stockholders' deficit. No dividends planned. Risks include competition, regulatory issues, and economic factors.
8-K
Board refresh and meeting results
Evolus refreshed its board on June 5, 2025, with Simone Blank stepping down voluntarily amid no disagreements, paving the way for Albert White III's Audit Committee role. At the annual meeting that day, shareholders elected David Gill and Albert White III as Class I directors through 2028, ratified Ernst & Young as auditors for 2025, and approved executive pay on an advisory basis. Board changes signal steady governance. Votes showed strong support, yet some withheld on Gill.
8-K
CFO Beaver resigns voluntarily
Evolus announced the voluntary resignation of CFO Sandra Beaver, effective June 13, 2025, as she joins a private mental health tech firm; the move stems from no disagreements on operations or finances. The company, riding strong momentum from recent product launches and record revenues, relies on its seasoned finance team for a seamless interim transition while searching for a successor. No successor named yet.
IPO
Website
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
5.90-0.29
BIOE
Bio Essence Corp.
0.07+0.00
EBS
Emergent BioSolutions Inc.
9.40-0.07
EVH
Evolent Health, Inc
7.08-0.33
EVO
Evotec SE
4.15+0.02
EVOK
Evoke Pharma, Inc.
5.02-0.10
GALDY
GALDERMA GROUP AG
36.43+0.26
NSRX
Nasus Pharma Ltd.
7.75-0.65
SFWJ
Software Effective Solutions Co
0.00+0.00
ULTA
Ulta Beauty, Inc.
506.07-12.72